[Accessed on 4th November 2022] 6
Screening may be warranted in patients with one or more risk factors, such as gastric or small intestine resections, inflammatory bowel disease, use of metformin for more than four months, use of proton pump inhibitors or histamine H 2 blockers for more than 12 months, vegans or strict vegetarians, and adults older than 75 years
Our products are supplied strictly for laboratory research, so we are unable to advise on dosing or protocols
Scholten AM, Vermeulen E, Dhonukshe-Rutten RAM, et al
As of 2026, retatrutide has not received marketing authorisation from the MHRA or EMA and is only accessible within authorised clinical trials